OK so you thought the title of the other thread was out of date BUT unfortunately there is no way to edit thread titles.

So here is a new title

This one has got the charts at the top again & has a link to the old one.
http://www.moneyam.com/InvestorsRoom/posts.php?tid=5021

Hi Robstuff, I kept my eye on OXB this morning and got back in at 31.00p. It did look as though it was on the turn, so hopefully it will be. I still think they'll do a deal eventually with a big pharmaco (probably Sanofi) but heaven knows when - would really kick myself if I were to miss it.

Very reassuring news out today - see the RNS. Commenting on the slide in share price and giving full update of various drug trials amd current cash position.

see what i mean, should rise back to 50 before xmas now

Moving now up 13%, about time.

OXFORD BIOMEDICA RESPONDS TO SHARE PRICE MOVEMENT AND REPORTS BUSINESS UPDATE

http://moneyam.uk-wire.com/cgi-bin/articles/200710250701003178G.html

Agreed, an excellent and timely RNS. Onwards & upwards from here.

RNS today explains about a patent dispute that OXB and Sigma-Aldrich are fighting in the US against Open Biosystems.

It seems they should win this: "In his order U.S. District Judge Charles A. Shaw concluded 'that the constructions of the disputed terms and phrases proposed by plaintiff are correct'."

However, it's always a distraction to a business and could keep the sp subdued for a while - that has tended to be the case with other pharmacos until the legal arguments are resolved.

You can read the full statement here:

http://www.londonstockexchange.com/LSECWS/IFSPages/MarketNewsPopup.aspx?id=1611227&source=RNS

OXB has got off to a good start at 34.0-35.5 so perhaps investors will see the positives in the statement?

UK smallcap opening - Oxford BioMedica firmer after favourable patent ruling - AFX

LONDON (Thomson Financial) - Shares in gene therapy company Oxford BioMedica ticked up a 1/4 penny to 33.5 in early deals after a favourable ruling in its patent dispute with Open Biosystems which confirms the strength and validity of certain intellectual property rights.

The ruling was part of the construction of patent claim terms in the patent infringement suit brought against Open Biosystems.

The lawsuit alleges that Open Biosystems infringes US Patent Nos. 6,924,123 and 7,056,699 entitled Lentiviral LTR Deleted Vector, which are owned by Oxford BioMedica and exclusively licensed to Sigma-Aldrich for research use, by selling, among other products, Open Biosystems' Lentiviral shRNAmir Library.

Good news Indeed! once you have a ruling that gives Oxb rights and more deals will follow if other Bios wish t use the science. Upwards from here, Oxbs share price is always late to respond I think due to the complex nature of the business - analysts need a bit of time before the institutions pile in.

Are you sure it is still upwards, Robstuff, or are you seeing an inverted graph?

hlyeo98
The graph does look a bit grap but OXB will recover.

these awful troughs have always been fantastic opportunities in the past - see the longer term graph at top of board. Always around this time of yr aswell. I'm still topping up at these prices

Certainly an expert on graphs you are, robstuff, predicting hitting 70p...time will tell.

Hlyeo98 you obviously know nothing about this company.It is in it's most exciting phase in it's history with potentially massive blockbusting products not far off, take a look at advfn.com to find out more from doctors and bioscience experts, Trovax alone could transform OXB share price into many pounds. Hlyeo this is a very dangerous time to be shorting this stock which i assume you are doing so take care. Also the graph has now shown a double bottom and the 6mth target would indicate 70p, a great opportunity to get in cheap or top up as has a director yesterday and myself

To me, the recent fall in the sp indicates that the Big Deal is perhaps receding into the distance - that's not to say it will not happen eventually; I'm sure it will. However, I have to confess that I sold out again when the tide turned a few days ago. These pharmacos can be very volatile, and I'd rather not incur too many heavy losses. The time to buy back, I think, is when there is clear upward movement again - and I'm not convinced today is the day.

Post 1041 looks like it is Hlyeo98 posting to himself - or is my Browser rendering incorrectly?

Toya, I don't think the Big Deal is that far off, indeed the Sanofi-deal rather confirms that Big-Pharma are willing to commit before the final whistle.

However the current sp fall is more to do with the Patent problem - for if this does go the wrong way it will mean that what OXB is offering is worth a lot less than we hoped.... . and "if anything" . . might be the perception.
Nevertheless, the recent ann. about the Legal Case appears to conform it is Good....but that's not to say it will be resolved in OXB's favour.

There is also the spectre of a general melt-down in stocks and if you want a further reason: - the fall in exchange-rate which means that any US-based profits ( of deal!) will be worth a lot less than a couple of years ago.

I sold some about 3 months ago.

Hangon, the post was from post 1023 from robstuff.

The chance is greater for the patent to go through than not. At the moment the price is very good and I think it is really time for the big buys and hold without any panic.

Announced today:

Oxford, UK: 29 November 2007: Oxford BioMedica (LSE: OXB), a leading gene
therapy company, announced today that it has been presented with the techMARK
2007 Achievement of the Year award for its collaboration with sanofi-aventis.
The techMARK Awards, organised by the London Stock Exchange, are designed to
reward outstanding achievement in the technology market. Professor Alan
Kingsman, Oxford BioMedica's Chief Executive Officer, collected the award last
night during the ceremony held at the InterContinental Hotel in London.



Professor Kingsman commented: 'The sanofi-aventis deal was a transformational
event for Oxford BioMedica that provides both near and long-term value as well
as clear endorsement of our most advanced product. I am honoured to receive this
prestigious award. It is a testament to the achievement of the entire team at
Oxford BioMedica.'

It was certainly a transformational deal - the sp has been suffering ever since!

I don't hold any stock currently as I now take the view that it's best to sell when I see the worm turn. By the same token, I do keep this on my watchlist, just in case...

It's a crazy old World. I thought we'd be heading towards a 1 for sure by now but then what do I know!